186
Omalizumab in children with allergic
asthma
1
Lanier B,
et al
.
J Allergy Clin Immunol
2009;124:1210–6;
2
Kulus M,
et al
.
Curr Med Res Opin
2010;26:1285–93;
3
Milgrom H,
et al
.
Pediatrics
2001;108:e36;
4
Busse W,
et al
.
N E
n
gl J Med
2011;364:1005–15
IA05
1
Moderate‐to‐severe
N=628
Exacerbations
52 Weeks
Severe
N=246
Exacerbations
52 Weeks
IA05-EU
2
010
3
Persistent asthma
(any severity)
N=419
Symptom‐free days
60 Weeks
ICATA
4
Omalizumab reduced
exacerbations
over 28 weeks in children with
moderate‐to‐severe allergic
asthma
Moderate‐to‐severe
Severe
NNT with omalizumab to prevent one clinically
significant exacerbation* per year was low
*Worsening of symptoms requiring rescue systemic corticosteroids for ≥3 days and/or doubling of baseline ICS
**p<0.001
ICS = inhaled corticosteroids; NNT = number needed to treat
Lanier B,
et al
. ERS 2010 (poster)
1.4
1.7
NNT to prevent
one exacerbation
IA05
IA05-EU
50%
Reduction in exacerbations
43%
Reduction in exacerbations
**
**
Simposium
